Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
详细信息 查看全文
- 作者：Sonata Jodele1 ; sonata.jodele@cchmc.org" class="auth_mail" title="E-mail the corresponding author ; Tsuyoshi Fukuda2 ; Kana Mizuno2 ; Alexander A. Vinks2 ; Benjamin L. Laskin3 ; Jens Goebel4 ; Bradley P. Dixon4 ; Ranjit S. Chima5 ; Russel Hirsch6 ; Ashley Teusink7 ; Danielle Lazear7 ; Adam Lane1 ; Kasiani C. Myers1 ; Christopher E. Dandoy1 ; Stella M. Davies1
- 关键词：Thrombotic microangiopathy ; Eculizumab ; CH50 ; Membrane attack complex ; Complement ; sC5b-9
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：22
- 期：2
- 页码：307-315
- 全文大小：1631 K
文摘
- •
Eculizumab is a promising therapeutic option in HSCT recipients with high-risk TMA.
- •
Eculizumab clearance in HSCT recipients depends on TMA disease activity.
- •
Plasma sC5b-9 concentration can be used to determine eculizumab dosing regimen.
- •
CH50 monitoring aids decision to discontinue therapy when TMA is controlled.
- •
PK/PD-guided eculizumab therapy improves survival in HSCT recipients with TMA.